We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
AQST

Price
3.25
Stock movement up
+0.03 (0.77%)
Company name
Aquestive Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
473.01M
Ent value
550.49M
Price/Sales
8.03
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-46.61%
1 year return
-8.22%
3 year return
37.62%
5 year return
-11.32%
10 year return
-
Last updated: 2025-09-12

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

AQST does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales8.03
Price to Book-
EV to Sales9.35

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count120.97M
EPS (TTM)-0.39
FCF per share (TTM)-0.38

Income statement

Loading...
Income statement data
Revenue (TTM)58.90M
Gross profit (TTM)40.87M
Operating income (TTM)-21.10M
Net income (TTM)-35.19M
EPS (TTM)-0.39
EPS (1y forward)-0.53

Margins

Loading...
Margins data
Gross margin (TTM)69.39%
Operating margin (TTM)-35.83%
Profit margin (TTM)-59.75%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash77.89M
Net receivables9.68M
Total current assets96.57M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment52.52M
Total assets109.96M
Accounts payable7.57M
Short/Current long term debt36.87M
Total current liabilities15.15M
Total liabilities155.38M
Shareholder's equity-45.42M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-34.21M
Capital expenditures (TTM)160.00K
Free cash flow (TTM)-34.37M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-32.01%
Return on Invested Capital257.64%
Cash Return on Invested Capital251.63%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.85
Daily high3.99
Daily low3.82
Daily Volume1.33M
All-time high18.96
1y analyst estimate8.42
Beta1.99
EPS (TTM)-0.39
Dividend per share-
Ex-div date-
Next earnings date10 Nov 2025

Downside potential

Loading...
Downside potential data
AQSTS&P500
Current price drop from All-time high-79.38%-1.46%
Highest price drop-96.68%-56.47%
Date of highest drop1 Jul 20229 Mar 2009
Avg drop from high-77.21%-10.99%
Avg time to new high198 days12 days
Max time to new high1748 days1805 days
COMPANY DETAILS
AQST (Aquestive Therapeutics Inc) company logo
Marketcap
473.01M
Marketcap category
Small-cap
Description
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Employees
142
Investor relations
-
SEC filings
CEO
Keith J. Kendall
Country
USA
City
Warren
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...